What happened with QGEN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
QIAGEN helps clinical and research laboratories extract DNA, RNA and proteins from biological samples, test them and interpret the results. Its kits, instruments, automation and analysis software connect these steps. Customers include healthcare testing laboratories, universities, pharmaceutical and biotechnology companies, and laboratories doing applied work such as forensics.
Customers buy directly from QIAGEN or through distributors. Consumable kits account for most sales, rather than instrument purchases; software and related services also contribute revenue. This makes continued use of its testing workflows important to the business. For systems such as QIAstat-Dx, expanding the range of available test panels helps support instrument adoption and demand for consumables.
Research demand depends partly on customers’ research budgets and grant funding, while diagnostic demand is influenced by insurers’ and government programs’ coverage and payment decisions. Clinical products also need applicable marketing authorizations and ongoing regulatory compliance, which determine where QIAGEN can sell them.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
QIAGEN’s results hinge on molecular-testing volumes and research consumables demand, with bioMérieux and Roche important diagnostic rivals to watch outside this list.
Bio-Rad competes with QIAGEN for the same laboratories’ spending on instruments and consumables that measure DNA and RNA, including digital PCR systems. Watch Bio-Rad’s research consumables demand alongside QIAGEN’s QIAcuity consumables, which offset weaker instrument sales in 2025.
Thermo Fisher Scientific competes with QIAGEN for laboratory purchases through Applied Biosystems and Invitrogen, selling products that prepare samples, amplify DNA with PCR instruments and run molecular assays using consumables.
Danaher competes for QIAGEN’s clinical testing customers through Cepheid systems that perform molecular tests, while its life-science businesses also sell to QIAGEN’s research customers.
Revvity competes with QIAGEN for research and clinical laboratories’ purchases of DNA amplification and genomic analysis products, diagnostic reagents and software. Its PCR and sequencing workflow business is the part to watch against QIAGEN’s research consumables and genomic analysis software.
Agilent Technologies competes with QIAGEN for research and clinical laboratory spending on genomics consumables, analysis software and tests that help guide drug selection, known as companion diagnostics. Watch those offerings rather than Agilent’s broader instrument business when comparing it with QIAGEN.
Illumina competes with QIAGEN to sell genomic research and molecular diagnostic laboratories kits that prepare DNA for sequencing and tools that analyze the results. Watch its library-preparation and analysis offerings alongside QIAGEN’s sequencing consumables, which can be used on any sequencer.
QuidelOrtho Corporation competes with QIAGEN to supply hospitals and clinical laboratories with molecular infectious-disease testing systems and the assays they repeatedly buy to use them. Watch assay purchases: QuidelOrtho’s instrument-placement contracts can require ongoing consumables purchases, while QIAGEN’s QIAstat-DX growth in 2025 reflected both instrument placements and consumables demand.
10x Genomics, Inc. competes for laboratories’ single-cell research consumables spending with the Parse Biosciences offerings QIAGEN acquired. The overlap to watch is consumables used to study individual cells, rather than 10x’s full research portfolio.
Bio-Techne and QIAGEN depend on research spending by academic and biopharmaceutical laboratories: Bio-Techne sells reagents and analytical systems, while QIAGEN sells sample-processing and assay products. Watch Bio-Techne’s research reagent demand for a read on the customer budgets that also affect QIAGEN’s sales.
SOPHiA GENETICS SA both competes with QIAGEN Digital Insights in genomic analysis software and uses QIAGEN consumables in testing bundles sold to hospitals, laboratories and biopharma companies. Watch its paid clinical analyses, since customers pay per analysis, while its bundled workflows also use QIAGEN products.
Avantor and QIAGEN draw on the same biopharmaceutical and academic laboratories’ consumables budgets: Avantor sells reagents, sample-preparation kits and laboratory supplies, while QIAGEN sells sample-processing and assay consumables. Watch Avantor’s laboratory consumables demand as a read on the research spending that supports QIAGEN’s sample-kit sales.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher’s report will show whether laboratories are buying sample-preparation and PCR products, areas where it competes with QIAGEN for their budgets.
Compare Thermo Fisher’s comments on demand for sample-preparation and PCR products with QIAGEN’s own consumables sales. Strong demand at Thermo Fisher would show that labs are still buying products for workflows similar to QIAGEN’s; weaker demand would point to tighter budgets in those shared purchasing areas and more pressure on QIAGEN’s related consumables.
Avantor, Inc. earningsAVTR
Avantor’s laboratory-supplies demand offers a read on purchases by academic and biopharmaceutical labs, which also buy QIAGEN’s sample-processing and assay consumables.
Read Avantor’s demand for reagents and laboratory supplies alongside QIAGEN’s consumables sales. Firm demand at Avantor together with growth in QIAGEN’s consumables would suggest shared customers are still funding research purchases; if Avantor demand weakens and QIAGEN’s sample-processing consumables also slow, tighter lab budgets are reaching QIAGEN through those customers.
Illumina Inc earningsILMN
Illumina’s report will show demand for sequencing-preparation and analysis products, while QIAGEN sells NGS consumables that laboratories can use with different sequencers.
Compare Illumina’s comments on demand for library-preparation and analysis products with QIAGEN’s sales of universal NGS consumables. Strong demand at both would point to active sequencing purchases that can benefit both companies. If Illumina’s products are strong but QIAGEN’s consumables weaken, a busy market is not translating into sales for QIAGEN’s universal products. Weakness at both would suggest sequencing-lab purchases are cooling.
QIAGEN N.V. earningsThis company
Most of QIAGEN’s revenue comes from consumables and related sales, and this report will show whether laboratories are still buying its kits, sample-processing products and related services.
Read consumables and related sales alongside instrument sales. If consumables keep growing even while instruments are weak, laboratories are still buying for their testing and sample-processing workflows. If consumables slow while instruments also remain weak, recurring purchases are not making up for soft equipment demand, leaving QIAGEN’s main source of revenue with less support.
SOPHiA GENETICS SA earningsSOPH
SOPHiA GENETICS SA’s report will show whether customers are paying for clinical genomic analyses and whether its testing bundles continue to use QIAGEN consumables.
Read SOPHiA GENETICS SA’s paid clinical-analysis activity alongside whether its bundled tests continue to use QIAGEN products. More paid analyses with QIAGEN consumables still in the bundles would suggest software demand is also supporting QIAGEN product sales. Less analysis activity, or bundles that no longer use QIAGEN consumables, would mean less sales support for QIAGEN through this connection.
Bio-Rad Laboratories, Inc. earningsBIO
Bio-Rad’s research-consumables demand will show whether laboratories are buying into digital-PCR workflows that also use QIAGEN’s QIAcuity consumables.
Compare Bio-Rad’s research-consumables demand with QIAGEN’s QIAcuity consumables sales. Firm demand at Bio-Rad alongside QIAGEN growth would suggest laboratories are still running digital-PCR workflows, supporting QIAGEN’s repeat consumables sales. If both weaken, research budgets for this workflow may be tightening, making it harder for QIAGEN’s consumables to carry growth while instrument sales are soft.
QuidelOrtho Corporation earningsQDEL
QuidelOrtho’s report will show whether hospitals and clinical labs are buying more molecular infectious-disease assays, a recurring-sales test for QIAGEN’s QIAstat-DX business.
Read QuidelOrtho’s system placements alongside follow-on assay purchases, then compare that pattern with QIAGEN’s QIAstat-DX placements and consumables demand. Placements that lead to ongoing assay purchases show installed systems generating repeat sales. If placements rise but assay purchases lag, installations are not yet translating into steady consumables revenue, a key link in QIAGEN’s own growth path.
10x Genomics, Inc. earningsTXG
10x Genomics’ report can show demand for single-cell research consumables, the niche where it competes with QIAGEN’s acquired Parse Biosciences offering.
Look at 10x Genomics’ comments on single-cell research consumables and whether QIAGEN’s related sales are supported. Strong demand at 10x alongside growth in QIAGEN’s offering would suggest research purchases in this niche remain active; weakness at both would point to a smaller budget pool for expanding QIAGEN’s acquired product line.
